7月2日，Abivax S.A.盘中上涨5.39%，报140.67美元/股，成交额6686.63万美元。
消息面上，公司宣布其ADS公开发行的承销商已全额行使超额配售权，额外购买96万股ADS，总募集金额从8亿美元提升至约9.2亿美元（净收益约8.74亿美元），预计下周一完成交割。募集资金将用于核心药物obefazimod在美国的商业化推进、溃疡性结肠炎及克罗恩病临床研发及一般企业用途。此次发行规模从最初的6亿美元连续上调至8亿美元再到9.2亿美元，反映机构认购需求极为旺盛。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹，当前股价持续高于每股125美元的发行价运行，超额配售全额行使进一步强化市场信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.